Trump Accelerates Psychedelic Drug Research for Veterans

Donald Trump signed an executive order to expedite FDA reviews of psychedelic drugs like ibogaine for medical use. This initiative aims to assist U.S. veterans battling PTSD. The order has prompted federal research funding, pushing for mental health treatment advancements and reclassification of these substances.

On Saturday, President Donald Trump signed an executive order aimed at speeding up access to medical research on psychedelic drugs, particularly for treating conditions like PTSD in veterans.

The order demands that the FDA expedite its reviews of drugs such as ibogaine, which have been gaining attention for their potential mental health benefits.

With $50 million dedicated to ibogaine research and support from influential figures, Trump aims to reclassify these substances, promising a new era for mental health treatments.

(With inputs from agencies.)